[Study of practices: What do general practitioners first propose when faced with asymptomatic lower extremity peripheral artery disease?]

Ann Cardiol Angeiol (Paris). 2020 Apr;69(2):55-59. doi: 10.1016/j.ancard.2020.03.001. Epub 2020 Mar 30.
[Article in French]

Abstract

Introduction: Peripheral artery disease of lower limbs (PAD) can be discovered at an asymptomatic stage by the realization of systolic pressure indices. The 2006 recommendations of the French National Authority for Health on AOMI encourage the systematic prescription of antiplatelet agents; the 2012 recommendations on the proper use of antiplatelet agents no longer encourage it in the case of asymptomatic PAD. These two recommendations still coexist. Our objective was to determine the management of an asymptomatic PAD by general practitioners.

Methods: Descriptive and analytical epidemiological study, with analysis of practices, prospectively addressed by postal questionnaire to a randomized sample of 220 GPs practicing in the European Metropolis of Lille between December 15, 2016 and February 15, 2017. The question was: "if an asymptomatic PAD is discovered in a 50-year-old patient who is otherwise in good general condition, what do you generally do?"

Results: Our sample was 92 general practitioners (42% participation). Of these, only 6 were practicing HPIs. Before an asymptomatic PAD, management included an opinion from an angiologist (84%) and/or a cardiologist (75%) before the drug was prescribed (antiplatelet agent for 57%, statin for 33% and ACE inhibitor for 14%).

Conclusion: The extension assessment was carried out in more than 8 out of 10 cases. The use of antiplatelet antiaggregants was significant, which can be explained by the coexistence of divergent recommendations. The rapid clarification of recommendations is essential with the evolution of scientific data.

Keywords: Arterial occlusive diseases; Artériopathies oblitérantes; Overprescribing; Surprescription.

Publication types

  • Observational Study

MeSH terms

  • Adrenergic Antagonists / therapeutic use
  • Adult
  • Aged
  • Asymptomatic Diseases / therapy*
  • Cross-Sectional Studies
  • Female
  • France
  • General Practitioners*
  • Health Care Surveys / statistics & numerical data
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Lower Extremity / blood supply*
  • Male
  • Middle Aged
  • Peripheral Arterial Disease / therapy*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Practice Guidelines as Topic
  • Practice Patterns, Physicians'*
  • Prospective Studies
  • Referral and Consultation / statistics & numerical data
  • Smoking Cessation

Substances

  • Adrenergic Antagonists
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Platelet Aggregation Inhibitors